Sierra Oncology (SRRA) Announces Momelotinib Achieved Statistically Significant Benefit on Symptoms, Anemia and Splenic Size in the Pivotal MOMENTUM Study for Myelofibrosis
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/24/2024
Go back to Sierra Oncology (SRRA) Announces Momelotinib Achieved Statistically Significant Benefit on Symptoms, Anemia and Splenic Size in the Pivotal MOMENTUM Study for Myelofibrosis
January 26, 2022 11:49 AM EST
Sierra Oncology (NASDAQ: SRRA) Adds to Yesterday's Gain, Up 18%
...
More
January 25, 2022 9:43 AM EST
Sierra Oncology (NASDAQ: SRRA) Halted on Volatility, Up 64%
...
More
January 25, 2022 7:19 AM EST
Sierra Oncology (NASDAQ: SRRA) to Resume Trading at 7:30 a.m.
...
More
